Macrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy

HomeCirculation ResearchVol. 134, No. 2Macrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextMacrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy Prabhash Kumar Jha, Masanori Aikawa and Elena Aikawa Prabhash Kumar JhaPrabhash Kumar Jha Center for Excellence in Vascular Biology (P.K.J., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston. , Masanori AikawaMasanori Aikawa https://orcid.org/0000-0002-9275-2079 Center for Excellence in Vascular Biology (P.K.J., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston. Center for Interdisciplinary Cardiovascular Sciences (M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston. Channing Division of Network Medicine (M.A.), Brigham and Women's Hospital, Harvard Medical School, Boston. and Elena AikawaElena Aikawa Correspondence to: Elena Aikawa, MD, PhD, Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, 77 Ave Louis Pasteur, NRB741, Boston, MA 02115. Email E-mail Address: [email protected] https://orcid.org/0000-0001-7835-2135 Center for Excellence in Vascular Biology (P.K.J., M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston. Center for Interdisciplinary Cardiovascular Sciences (M.A., E.A.), Brigham and Women's Hospital, Harvard Medical School, Boston. Originally published18 Jan 2024https://doi.org/10.1161/CIRCRESAHA.123.324011Circulation Research. 2024;134:186–188This article is a commentary on the followingCD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing EfferocytosisFootnotesFor Sources of Funding and Disclosures, see page 188.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Elena Aikawa, MD, PhD, Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, 77 Ave Louis Pasteur, NRB741, Boston, MA 02115. Email eaikawa@bwh.harvard.eduREFERENCES1. Rogers MA, Aikawa M, Aikawa E. Macrophage heterogeneity complicates reversal of calcification in cardiovascular tissues.Circ Res. 2017; 121:5–7. doi: 10.1161/CIRCRESAHA.117.311219LinkGoogle Scholar2. Barrett TJ. Macrophages in atherosclerosis regression.Arterioscler Thromb Vasc Biol. 2020; 40:20–33. doi: 10.1161/ATVBAHA.119.312802LinkGoogle Scholar3. Fredman G, MacNamara KC. Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect.Cardiovasc Res. 2021; 117:2563–2574. doi: 10.1093/cvr/cvab309CrossrefMedlineGoogle Scholar4. Gerlach BD, Ampomah PB, Yurdagul A, Liu C, Lauring MC, Wang X, Kasikara C, Kong N, Shi J, Tao W, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury.Cell Metab. 2021; 33:2445–2463.e8. doi: 10.1016/j.cmet.2021.10.015CrossrefMedlineGoogle Scholar5. Kojima Y, Volkmer J-P, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.Nature. 2016; 536:86–90. doi: 10.1038/nature18935CrossrefMedlineGoogle Scholar6. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm.J Immunol. 2000; 164:6166–6173. doi: 10.4049/jimmunol.164.12.6166CrossrefMedlineGoogle Scholar7. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental guidelines.Immunity. 2014; 41:14–20. doi: 10.1016/j.immuni.2014.06.008CrossrefMedlineGoogle Scholar8. Decano JL, Aikawa M. Dynamic macrophages: understanding mechanisms of activation as guide to therapy for atherosclerotic vascular disease.Front Cardiovasc Med. 2018; 5:97. doi: 10.3389/fcvm.2018.00097CrossrefMedlineGoogle Scholar9. Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Amir E-aD, Amadori L, Khan NS, Wong CK, Shamailova R, Hill CA, et al. Single-cell immune landscape of human atherosclerotic plaques.Nat Med. 2019; 25:1576–1588. doi: 10.1038/s41591-019-0590-4CrossrefMedlineGoogle Scholar10. Decano JL, Maiorino E, Matamalas JT, Chelvanambi S, Tiemeijer BM, Yanagihara Y, Mukai S, Jha PK, Pestana DVS, D'Souza E, et al. Cellular heterogeneity of activated primary human macrophages and associated drug-gene networks: from biology to precision therapeutics.Circulation. 2023; 148:1459–1478. doi: 10.1161/CIRCULATIONAHA.123.064794LinkGoogle Scholar11. Mohd Idrus FN, Ahmad NS, Hoe CH, Azlan M, Norfuad FA, Yusof Z, Wan Isa WYH, Mohamed Ali AA, Yvonne-Tee GB. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.BMC Immunol. 2021; 22:21. doi: 10.1186/s12865-021-00410-2CrossrefMedlineGoogle Scholar12. Holden RM, Hetu MF, Li TY, Ward EC, Couture LE, Herr JE, Christilaw E, Adams MA, Johri AM. Circulating Gas6 is associated with reduced human carotid atherosclerotic plaque burden in high risk cardiac patients.Clin Biochem. 2019; 64:6–11. doi: 10.1016/j.clinbiochem.2018.11.018CrossrefMedlineGoogle Scholar13. Nepal S, Tiruppathi C, Tsukasaki Y, Farahany J, Mittal M, Rehman J, Prockop DJ, Malik AB. STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation.Proc Natl Acad Sci U S A. 2019; 116:16513–16518. doi: 10.1073/pnas.1821601116CrossrefMedlineGoogle Scholar14. Lv J-J, Zhang H, Zhang T-J, Wei H-L, Liu Z-K, Ma Y-H, Yang Z, He Q, Wang L-J, Duan L-L, et al. CD147 destabilizes atherosclerotic lesions by promoting the M1 macrophage phenotype and impairing clearance of apoptotic cells.Circ Res. 2023; 134:165–185. doi: 10.1161/CIRCRESAHA.123.323223LinkGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesCD147 Sparks Atherosclerosis by Driving M1 Phenotype and Impairing EfferocytosisJian-Jun Lv, et al. Circulation Research. 2024;134:165-185 January 19, 2024Vol 134, Issue 2 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.123.324011PMID: 38236949 Originally publishedJanuary 18, 2024 KeywordsEditorialscell deathefferocytosisinflammationmacrophagesosteoclastsPDF download Advertisement